Mark Selby

Biography

Mark’s team is responsible for exploring and validating new targets and developing fully human antibodies for clinical evaluation in oncology. The targets of interest are those that promote immune suppressive tumor environments and include, but are not limited to, positive and negative co-stimulators. Mark also directly supervises four Ph.D. scientists who are working on multiple antibody programs in both early and late stage development. Mark has worked at Bristol-Myers Squibb and Medarex (before it was acquired by Bristol-Myers Squibb in 2009) for over 15 years, focusing his research on anti-PD-1, anti-PD-L1, anti-PD-1 + anti-CTLA-4, anti-LAG-3 and anti-GITR. He and his team have been responsible for moving preclinical antibody assets related to these targets, some of which are now approved for oncology indications. Prior to his work at Medarex/Bristol-Myers Squibb, Mark worked as a scientist at the biopharmaceutical company, Chiron, where he focused on vaccine research. Mark received his B.A. in Bacteriology from the University of California, Berkeley and his Ph.D. in microbiology from the University of California, San Francisco. He conducted his post-doctoral research in the Howard Hughes Medical Institute at the University of California, San Francisco, where he was responsible for investigating the mechanism of Tat transactivation of the HIV-1 LTR. Mark has also authored or co-authored 60 publications.

Research Interest

where he was responsible for investigating the mechanism of Tat transactivation of the HIV-1 LTR.